New River Pharmaceuticals clinical trials
Acquired by Takeda, Jan 8, 2019 · source ↗
The registry lists 6 studies whose lead sponsor is New River Pharmaceuticals. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 20, 2012.
Before and after it joined Takeda
- First submitted before New River Pharmaceuticals became part of Takeda
- 6
- First submitted after New River Pharmaceuticals became part of Takeda
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- New River Pharmaceuticals6 studies
Something wrong with this grouping? Tell us on the Takeda page.
Studies
Recruiting first, then most recently updated. Showing 6 of 6. All Takeda studies →
- An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)CompletedNCT00337285Phase 3
Sponsor listed in the registry: New River Pharmaceuticals · First submitted before New River Pharmaceuticals became part of Takeda
- Phase 3 Randomized Double-Blind Placebo-Controlled Study of NRP104 in Children Aged 6-12 With ADHDCompletedNCT00556296Phase 3
Sponsor listed in the registry: New River Pharmaceuticals · First submitted before New River Pharmaceuticals became part of Takeda
- NRP104, Adderall XR or Placebo in Children Aged 6-12 Years With ADHDCompletedNCT00557011Phase 2
Sponsor listed in the registry: New River Pharmaceuticals · First submitted before New River Pharmaceuticals became part of Takeda
- Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)CompletedNCT00334880Phase 3
Sponsor listed in the registry: New River Pharmaceuticals · First submitted before New River Pharmaceuticals became part of Takeda
- Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse HistoriesCompletedNCT00247572Phase 2
Sponsor listed in the registry: New River Pharmaceuticals · First submitted before New River Pharmaceuticals became part of Takeda
- Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant AbuseCompletedNCT00248092Phase 1/2
Sponsor listed in the registry: New River Pharmaceuticals · First submitted before New River Pharmaceuticals became part of Takeda